AR010339A1 - Derivado de benzamida heterociclica sustituida y su uso - Google Patents

Derivado de benzamida heterociclica sustituida y su uso

Info

Publication number
AR010339A1
AR010339A1 ARP970105766A ARP970105766A AR010339A1 AR 010339 A1 AR010339 A1 AR 010339A1 AR P970105766 A ARP970105766 A AR P970105766A AR P970105766 A ARP970105766 A AR P970105766A AR 010339 A1 AR010339 A1 AR 010339A1
Authority
AR
Argentina
Prior art keywords
benzamide derivative
cyclical
substituted hetero
disease
diseases
Prior art date
Application number
ARP970105766A
Other languages
English (en)
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of AR010339A1 publication Critical patent/AR010339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un derivado de benzamida heterocíclica sustituida de la formula I, sus formas tautomeras e isomeras, así como sus sales fisiologicamente aptas.Utiles para tratamiento de enfermedades neurodegenerativas y danos neuronales debidos a isquemias,t raumas o hemorragias masivas, infarto cerebral,enfermedades de Alzheimer y de Huntington, epilepsia, insuficiencia cardíaca y/o venal, tumores y metástasis, enfermedades inmunologicas y enfermedadesreumáticas.
ARP970105766A 1996-12-09 1997-12-09 Derivado de benzamida heterociclica sustituida y su uso AR010339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19650975A DE19650975A1 (de) 1996-12-09 1996-12-09 Neue heterocyclisch substituierte Benzamide und deren Anwendung

Publications (1)

Publication Number Publication Date
AR010339A1 true AR010339A1 (es) 2000-06-07

Family

ID=7814035

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105766A AR010339A1 (es) 1996-12-09 1997-12-09 Derivado de benzamida heterociclica sustituida y su uso

Country Status (24)

Country Link
US (2) US6172072B1 (es)
EP (1) EP0946509A1 (es)
JP (1) JP2001505889A (es)
KR (1) KR20000057445A (es)
CN (1) CN1239949A (es)
AR (1) AR010339A1 (es)
AU (1) AU742732B2 (es)
BG (1) BG63388B1 (es)
BR (1) BR9713884A (es)
CA (1) CA2273988A1 (es)
CO (1) CO4910161A1 (es)
CZ (1) CZ292391B6 (es)
DE (1) DE19650975A1 (es)
HR (1) HRP970671A2 (es)
HU (1) HUP0000496A3 (es)
ID (1) ID22490A (es)
IL (1) IL129358A0 (es)
NO (1) NO992770D0 (es)
NZ (1) NZ335066A (es)
SK (1) SK56699A3 (es)
TR (1) TR199901282T2 (es)
TW (1) TW420666B (es)
WO (1) WO1998025899A1 (es)
ZA (1) ZA9710979B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003071T2 (tr) * 1998-04-20 2001-04-20 Basf Aktiengesellschaft Sistein-proteazı önleyici etkiye sahip yeni heterosiklik ikame edilmiş amidler
JP2003513092A (ja) * 1999-11-05 2003-04-08 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） 新規複素環化合物及びその医薬としての使用
FR2800737B1 (fr) * 1999-11-05 2006-06-30 Sod Conseils Rech Applic Nouveaux composes heterocycliques et leur application a titre de medicaments
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
EP1562897B1 (en) 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
EP1657238A4 (en) * 2003-08-22 2008-12-03 Takeda Pharmaceutical MERGED PYRIMIDINE DERIVATIVE AND USE THEREOF
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
FR2863268B1 (fr) * 2003-12-09 2006-02-24 Sod Conseils Rech Applic Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
EP2615087A3 (en) * 2003-12-22 2013-08-07 Ajinomoto Co., Inc. Phenylalanine derivatives
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
EP2439205B1 (en) 2006-12-29 2015-03-11 AbbVie Deutschland GmbH & Co KG Carboxamide compounds and their use as calpain inhibitors
CA2680275C (en) 2007-03-09 2016-08-23 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
TWI453019B (zh) 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US8598211B2 (en) 2009-12-22 2013-12-03 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors IV
US9051304B2 (en) 2009-12-22 2015-06-09 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors V
WO2011137372A1 (en) 2010-04-30 2011-11-03 Abbott Cardiovascular Systems Inc. Improved balloon catheter exhibiting rapid inflation and deflation
WO2012076639A1 (en) 2010-12-09 2012-06-14 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors v
JP2015512427A (ja) 2012-04-03 2015-04-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー カルボキサミド化合物およびそれのカルパイン阻害薬ｖとしての使用
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
CN110023304A (zh) 2016-09-28 2019-07-16 布莱德治疗公司 钙蛋白酶调节剂及其治疗用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
DE3717828A1 (de) * 1987-05-27 1988-12-15 Hoechst Ag Siliziumhaltige benzoesaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
DE4000204A1 (de) 1990-01-05 1991-07-11 Steag Ag Vorrichtung zum dosierten austragen von schuettfaehigem feststoff
EP0473551A1 (de) * 1990-08-31 1992-03-04 Ciba-Geigy Ag 3-Aryluracil-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Unkrautbekämpfungsmittel
AU667463B2 (en) 1990-12-28 1996-03-28 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
US5319085A (en) 1990-12-28 1994-06-07 Kyowa Hakko Kogyo Co., Ltd. Quinoline derivative having serotonin-3 receptor antagonizing activity
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
WO1994000095A2 (en) 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5541290A (en) 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds

Also Published As

Publication number Publication date
IL129358A0 (en) 2000-02-17
HUP0000496A3 (en) 2002-11-28
US6436949B1 (en) 2002-08-20
NO992770L (no) 1999-06-08
BG63388B1 (bg) 2001-12-29
CN1239949A (zh) 1999-12-29
SK56699A3 (en) 1999-10-08
ZA9710979B (en) 1999-06-18
CZ174399A3 (cs) 1999-08-11
US6172072B1 (en) 2001-01-09
KR20000057445A (ko) 2000-09-15
CZ292391B6 (cs) 2003-09-17
HRP970671A2 (en) 1998-10-31
TR199901282T2 (xx) 1999-10-21
HUP0000496A2 (hu) 2000-09-28
EP0946509A1 (de) 1999-10-06
BR9713884A (pt) 2000-02-29
AU742732B2 (en) 2002-01-10
ID22490A (id) 1999-10-21
DE19650975A1 (de) 1998-06-10
TW420666B (en) 2001-02-01
WO1998025899A1 (de) 1998-06-18
NZ335066A (en) 2000-03-27
BG103399A (en) 2000-01-31
NO992770D0 (no) 1999-06-08
CO4910161A1 (es) 2000-04-24
AU5558098A (en) 1998-07-03
JP2001505889A (ja) 2001-05-08
CA2273988A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
AR010339A1 (es) Derivado de benzamida heterociclica sustituida y su uso
CO4940418A1 (es) Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
UY24895A1 (es) Arilsulfonamidas y análogos útiles para el tratamiento de enfermedades neurodegenerativas
DE69737605D1 (de) Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
AR221354A1 (es) Procedimiento para la preparacion de nuevos derivados de 2-metoxi-4-amino 5-alquilsulfonil-n-(2-pirrolidil)-metil-benzamida,sus sales de adicion con acidos farmacologicamente aceptables,sus sales de amonio cuaternarias,sus n-oxidos y sus isomeros levogiros y dextrogiros
ES536499A0 (es) Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.
CO5031247A1 (es) Compuestos triciclicos sustituidos
DE59007531D1 (de) Verwendung des Wirkstoffs Azelastin zur Bekämpfung von Psoriasis-Erkrankungen.
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
FR2400898A1 (fr) Agents anti-inflammatoires pour produits cosmetiques
IT1164821B (it) Benzammidi eterocicliche sostituite procedimento per la loro produzione e loro impiego come modificatori di comportamento
ES2041705T3 (es) Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados.
AR224251A1 (es) Procedimiento para la obtencion de derivados de n-(3-fenoxi-2-hidroxi-propil)-n'-(2,4-diozo-pirimidil(6))-alquilendiamina de formula general i
ECSP003590A (es) Compuestos calcioliticos
MX9306035A (es) Nuevas bis-naftalimidas sustituidas en forma asimetrica.
SV1998000023A (es) Arilsulfonamidas y analogos ref. lea 32316-sv
NO20003828L (no) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinase inhibitorer
BR0317834A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìlico como inibidores mmp 13 seletivos
ES2036137B1 (es) Procedimiento para la preparacion de la nueva 1-(3-clorofenil)-4-hidroximetil-7,8-dimetoxi-5h-2,3-benzodiacepina y de sus sales de adicion acida.
ES2165233T3 (es) Empleo de 1-fosfato de esfingosina, derivados de 1-fosfato de esfingosina y/o sus mezclas para el tratamiento de enfermedades cutaneas inflamatorias.
ES2111891T3 (es) Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.
ES2020925B3 (es) Nuevas sales cristalinas de ariloxipropanolaminas, procedimiento para su preparacion y utilizacion de las mismas.
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
MX9300335A (es) Nuevas n-arilindolas y su uso como herbicidas.
ES2163450T3 (es) Utilizacion de benzidamina en el tratamiento de estados patologicos causados por tnf.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal